GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin

In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit seen for any one person was small, thousands could potentially see a benefit given the large number of people taking GLP-1s.d.